New combo therapy aims to cut hormone treatment for prostate cancer

This early-phase study tested a new approach for men with prostate cancer that has spread to nearby lymph nodes. The standard treatment combines radiation with 2-3 years of hormone therapy, which can cause lasting side effects. Researchers added a targeted radioactive drug (Lu-PSMA) to the radiation, hoping to better control the cancer and possibly reduce the need for long-term hormone therapy. The study involved 14 participants and focused on finding the safest dose of Lu-PSMA when given with radiation.